Literature DB >> 34351262

How Should Clinicians Minimize Harms and Maximize Benefits When Diagnosing and Treating Disorders Without Biomarkers?

Benjamin Tolchin1, Dorothy W Tolchin2, Michael Ashley Stein3.   

Abstract

Ethical obligations to minimize harms and maximize benefits of diagnosis and treatment of disorders without biomarkers include navigating difficult-to-measure, perhaps clinically inexplicable, symptoms. Among potential harms are public stigma, self-stigma, label avoidance, and the negative influence these stigmas have on self-esteem, quality of life, employment, and housing. Among potential benefits are patients becoming active agents in managing their illnesses, social acceptance, and access to evidence-based treatments. Ethical complexities clinicians face when trying to develop treatment plans while heeding key details from patients' narrative accounts prompt questions about how to best adhere to evidence in understudied domains of medicine.
© 2021 American Medical Association. All Rights Reserved.

Entities:  

Year:  2021        PMID: 34351262     DOI: 10.1001/amajethics.2021.530

Source DB:  PubMed          Journal:  AMA J Ethics


  1 in total

1.  Identifying the top research priorities in medically not yet explained symptoms (MNYES): a James Lind Alliance priority setting partnership.

Authors:  Christina Maria van der Feltz-Cornelis; Jennifer Sweetman; Mark Edwards; Nicholas Gall; Jennifer Gilligan; Stephanie Hayle; Arvind Kaul; Andrew Stephen Moriarty; Petros Perros; James Sampford; Natalie Smith; Iman Elfeddali; Danielle Varley; Jonathan Gower
Journal:  BMJ Open       Date:  2022-07-01       Impact factor: 3.006

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.